These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28460594)

  • 1. A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries.
    Haugh M; Gresset-Bourgeois V; Macabeo B; Woods A; Samson SI
    Expert Rev Vaccines; 2017 Jun; 16(6):545-564. PubMed ID: 28460594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V; Leventhal PS; Pepin S; Hollingsworth R; Kazek-Duret MP; De Bruijn I; Samson SI
    Expert Rev Vaccines; 2018 Jan; 17(1):1-11. PubMed ID: 29157068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluarix quadrivalent vaccine for influenza.
    Graaf Hd; Faust SN
    Expert Rev Vaccines; 2015; 14(8):1055-63. PubMed ID: 26098443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®.
    Latreille-Barbier M; Rouzier R; Astruc B; Lavis N; Donazzolo Y
    Hum Vaccin Immunother; 2017 Nov; 13(11):2674-2677. PubMed ID: 28937844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluzone® Intradermal Quadrivalent Influenza Vaccine.
    Robertson CA; Tsang P; Landolfi VA; Greenberg DP
    Expert Rev Vaccines; 2016 Oct; 15(10):1245-53. PubMed ID: 27457797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S; Donazzolo Y; Jambrecina A; Salamand C; Saville M
    Vaccine; 2013 Nov; 31(47):5572-8. PubMed ID: 24016810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
    Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
    Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.
    Bekkat-Berkani R; Ray R; Jain VK; Chandrasekaran V; Innis BL
    Expert Rev Vaccines; 2016; 15(2):201-14. PubMed ID: 26641539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent influenza vaccine (Sinovac Biotech) for seasonal influenza prophylaxis.
    Tao YY; Li JX; Hu YM; Hu YS; Zeng G; Zhu FC
    Expert Rev Vaccines; 2021 Jan; 20(1):1-11. PubMed ID: 33434084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip.
    Delore V; Salamand C; Marsh G; Arnoux S; Pepin S; Saliou P
    Vaccine; 2006 Mar; 24(10):1586-92. PubMed ID: 16271424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
    Arnoux S; Weinberger C; Gessner BD
    Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults.
    Montomoli E; Torelli A; Manini I; Gianchecchi E
    Vaccines (Basel); 2018 Mar; 6(1):. PubMed ID: 29518013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.